Who
Aaron Kantoff
Director
Company insider
Files Form 4 as: Director, Avalo Therapeutics; Director, Tourmaline Bio; Director, Centessa Pharmaceuticals.
In numbers
- Trades disclosed
- 26
- Buys
- 2
- Sells
- 0
- Bought
- $209K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 18 Nov 2021
- Last trade
- 2 Jun 2026
- Last filed
- 4 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jun 2026filed 4 Jun 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,166 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,166 at $0.00 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,166 at $0.00 | filing |
| 28 Mar 2026filed 31 Mar 2026 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,166 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code D | —16,800 | filing |
| 28 Oct 2025filed 28 Oct 2025 | Tourmaline Bio | SEC FORM 4 Code U | —88,281 | filing |
| 24 Oct 2025filed 24 Oct 2025 | Tourmaline Bio | SEC FORM 4 Code G | —5,000 at $0.00 | filing |
| 5 Sep 2025filed 9 Sep 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code M | —37,890 at $0.00 | filing |
| 5 Sep 2025filed 9 Sep 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 5 Sep 2025filed 9 Sep 2025 | Tourmaline Bio | SEC FORM 4 Code M | $4,92637,890 at $0.13 | filing |
| 5 Sep 2025filed 9 Sep 2025 | Tourmaline Bio | SEC FORM 4 Code M | $95K10,000 at $9.46 | filing |
| 17 Jun 2025filed 18 Jun 2025 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | Tourmaline Biooption or derivative | SEC FORM 4 Code A | —16,800 at $0.00 | filing |
| 28 Mar 2025filed 1 Apr 2025 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,167 at $0.00 | filing |
| 28 Mar 2025filed 1 Apr 2025 | AVTX Avalo TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,167 | filing |
| 13 Aug 2024filed 14 Aug 2024 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,600 at $0.00 | filing |
| 13 Aug 2024filed 14 Aug 2024 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.